About Pantarhin Pharma Inc.
Where everything flows into precision therapeutics.
Who We Are
PantarhinTM Pharma Inc. is a U.S. life-science company based in Tampa, Florida (organized May, 2025), developing enzyme-based approaches for cardiovascular health. We combine biological elegance with regulatory rigor and disciplined market access.
The focus is on innovative enzyme designs that influence pathological ECM structures in cardiovascular diseases, with the aim of creating new therapeutic options for serious genetic metabolic disorders and vascular diseases.
Our mission: To responsibly advance enzyme-based therapeutics through rigorous research and regulatory pathways toward enzyme-based therapeutics.
Science & Modality (D016)
- Enzyme-driven modality designed to interact with extracellular-matrix and lipid structures relevant to CV disease.
- Vialized supply format for scalability (15,000 IU per vial); per-patient therapy cycle target: 150-450,000 IU.
- Clinical translation pathway planned; claims will follow evidence and regulatory guidance.
We avoid product claims pending formal clinical evaluation and regulatory review.
Market & Access (U.S. Focus)
Our U.S. strategy contemplates a dual-channel model: Retail pharmacy partners (e.g., Big Pharma, CVS, Walgreens) and physician-guided care. Packaging, logistics and labeling will be aligned with applicable requirements and standard operating procedures.
Ethics, Quality & Compliance
- Non-promotional scientific communications; medical inquiries routed to qualified professionals.
- Regulatory pathway planning (FDA) and documentation aligned with Good Practices (GxP) and SOPs.
- Regulatory path: Clear roadmap from preclinical to clinical phases to potential approval,
supported by an experienced regulatory team. - Data protection and confidentiality for investor diligence (NDA workflows upon request).
Geographic Scope & Canada
The primary audience for this site is the United States.
Canada: Market evaluation in progress. No Health Canada authorization. No offer or solicitation in Canada. We are evaluating expansion to Canada; no Canadian authorization has been obtained and no offer or solicitation is intended in any Canadian province or territory. Canadian messaging, if pursued, will follow applicable laws and guidance.